Original Research
Accepted on 27 Dec 2024
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron-variant
in Health Economics
- 151 views
Original Research
Accepted on 27 Dec 2024
in Health Economics
Original Research
Accepted on 27 Dec 2024
in Health Economics
Original Research
Accepted on 27 Dec 2024
in Health Economics
Original Research
Accepted on 27 Dec 2024
in Health Economics
Original Research
Accepted on 26 Dec 2024
in Health Economics
Original Research
Accepted on 24 Dec 2024
in Health Economics
Original Research
Published on 24 Dec 2024
in Health Economics
Original Research
Accepted on 23 Dec 2024
in Health Economics
Original Research
Accepted on 23 Dec 2024
in Health Economics
Original Research
Accepted on 23 Dec 2024
in Health Economics
Original Research
Published on 23 Dec 2024
in Health Economics
Original Research
Published on 19 Dec 2024
in Health Economics
Original Research
Published on 19 Dec 2024
in Health Economics
Editorial
Accepted on 18 Dec 2024
in Health Economics
Original Research
Accepted on 18 Dec 2024
in Health Economics
Original Research
Accepted on 18 Dec 2024
in Health Economics